CME Group Inc. (CME) stock analysis
Close on Nov 12, 2026Market cap $112.93BP/E 25.9Yield 1.58%
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed9 of 30 checks passed
CME passes 9 of the 30 checks behind our score; 8 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 2/6
- Financial health
- 5/6
- Dividend
- 1/6
What stands out
Return on capital over 10%
Return on invested capital was 14.1%, above the 10% that usually covers the cost of capital.
No debt
CME has no borrowings on its latest balance sheet.
Earnings grew over 5 years
Net income grew 14.1% a year on average over the last five fiscal years.
EPS growing 10%+ a year
Diluted EPS grew 14.7% a year over the last three fiscal years.
What to watch
Margin of safety under 20%
The price is 20.2% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $315.87 is above our fair value estimate of $262.74.
Revenue growing under 10% a year
Revenue grew 9.1% a year over the last three fiscal years, short of the 10% we look for.
Elevated bankruptcy risk
The Altman Z-score is 0.59; above 3 is the safe zone and below 1.8 the distress zone.
Valuation0/6
P/E above its 5-year median
CME's P/E of 25.9 is above its own 5-year median of 25.2.
P/E above the industry
CME's P/E of 25.9 is above the Security & commodity brokers, dealers, exchanges & services median of 25.3.
EV/EBITDA above its 5-year median
CME's EV/EBITDA of 24.2 is above its 5-year median of 22.2.
P/B above the industry
CME's price-to-book of 4.26 is above the Security & commodity brokers, dealers, exchanges & services median of 4.26.
Trading above fair value
The share price of $315.87 is above our fair value estimate of $262.74.
Margin of safety under 20%
The price is 20.2% above fair value, so there is no margin of safety.
Growth1/6
Revenue growing under 10% a year
Revenue grew 9.1% a year over the last three fiscal years, short of the 10% we look for.
EPS growing 10%+ a year
Diluted EPS grew 14.7% a year over the last three fiscal years.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew 9.0% over the last twelve months; the Security & commodity brokers, dealers, exchanges & services median is 14.4%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance2/6
Return on equity
Needs positive equity and five years of results.
Return on capital over 10%
Return on invested capital was 14.1%, above the 10% that usually covers the cost of capital.
Return on equity against the industry
Needs positive equity.
Earnings grew over 5 years
Net income grew 14.1% a year on average over the last five fiscal years.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health5/6
No debt
CME has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 1.02 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is 0.59; above 3 is the safe zone and below 1.8 the distress zone.
Dividend1/6
Pays a dividend
CME paid dividends worth 3.6% of the share price over the last twelve months.
Yield below Treasuries
The 3.6% yield is below the 4.4% on a 1-year Treasury.
Yield below the top quarter
The top quarter of US dividend payers yield 3.8% or more; CME yields 3.6%.
Dividend was cut
The dividend per share fell by more than 10% at least once in the last 10 fiscal years.
Earnings cover
Needs dividends paid and net income.
Not covered by free cash flow
Dividends take 94.3% of free cash flow.
Fair value
How we estimate itOur estimate per share
$262.74
The share price is 20% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 25.2× | 25.2× | 25.3× | $307.56 | 40% |
| EV/EBITDA | 20.0× | 22.2× | 17.8× | $262.81 | 35% |
| P/B | 3.6× | 2.9× | 4.3× | $265.98 | 10% |
| Earnings power | 7.4% cost of equity | – | – | $140.92 | 15% |
| Fair value | $262.74 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 25.2
- Security & commodity brokers, dealers, exchanges & services median 25.3
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $593.07M
- Value traded per 1% price move
- $465.14M
Downside
Medium risk
- Typical loss in a bad month
- 16.7%
- Volatility (annualized)
- 25%
- Sharpe ratio, 1 year
- 0.38
- Beta to the S&P 500 (5Y)
- 0.36
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.4% | +9.1% | +6.0% | +7.0% | |
| Operating income | +7.6% | +11.9% | +9.9% | +7.8% | |
| Net income | +15.5% | +14.8% | +14.1% | +12.6% | |
| EPS, diluted | +15.4% | +14.7% | +13.7% | +11.7% | |
| Free cash flow | +16.6% | +12.2% | +10.7% | +11.5% | |
| Dividend per share | -51.9% | -16.2% | -3.3% | +0.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 7.5% | 8.0% | 14.8% | |
| Return on assets | 2.2% | 2.1% | 2.4% | |
| Current ratio | 1.03 | 1.01 | 1.03 | |
| Capex to revenue | 2.6% | 4.0% | 1.3% | |
| Diluted shares | 339M | 359M | 360M |
Where the cash went
Fiscal 2021 to 2025, five years combined
CME generated $16.88B from operations and spent $16.05B on capital expenditure, dividends and share buybacks. 3% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 62.5% | 0.04× | 6.08× | 14.8% |
| FY2024 | 57.5% | 0.05× | 5.02× | 13.2% |
| FY2023 | 57.8% | 0.04× | 5.67× | 12.0% |
| FY2022 | 53.6% | 0.03× | 6.83× | 9.9% |
| FY2021 | 56.2% | 0.03× | 5.98× | 9.8% |
| FY2020 | 43.1% | 0.05× | 3.81× | 8.0% |
| FY2019 | 43.5% | 0.06× | 2.93× | 8.1% |
| FY2018 | 45.5% | 0.06× | 3.17× | 8.1% |
| FY2017 | 111.5% | 0.05× | 3.40× | 19.0% |
| FY2016 | 42.7% | 0.05× | 3.34× | 7.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$4.07B
- Cash generatingOperating cash flow above zero$4.28B
- Return on assets improvedROA up on the prior year2.7% → 3.0%
- Earnings backed by cashOperating cash flow above net income$4.28B vs $4.07B
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.01 → 1.03
- No dilutionShare count did not rise360M → 360M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.05 → 0.05
See a number that looks wrong?